SA Editor Douglas W. House
Healthcare, Biotech

The Evolution Of Compugen: Is The Titan Arum Finally Ready To Bloom?

On August 5, shares of Israel-based drug discovery firm Compugen (NASDAQ:CGEN) popped ~45% in response to its disclosure of a potentially lucrative collaboration agreement with Bayer. CGEN will receive an upfront payment of $10M and potentially as much as $530M based on the achievement of certain milestones relative to the commercial development of two of CGEN's immune checkpoint regulators, CGEN-15001T and CGEN-15022. Upon regulatory clearance, CGEN will receive high single-digit royalties on global net sales. The contract has the potential to be CGEN's largest (by far) in its 20-year corporate life and deliver a profound fundamental boost to the firm considering its miniscule revenues of ~$600k (NYSE:TTM).

It doesn't take much scrutiny, though, to see that...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details